Dai-Fang Liu
Research Subjects
Dai-Fang Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
John C. McMichael
Wyeth Vaccines Research, Pearl River, New York 10965
2 shared publicationsSteven M. Baker
Wyeth Vaccines Research, Pearl River, New York 10965
2 shared publicationsBruce A. Green
Wyeth Vaccines Research, Pearl River, New York 10965,1 Edward Mallinckrodt Department of Pediatrics and Department of Molecular Microbiology, Washington University School of Medicine, and Division of Infectious Diseases, St. Louis Children's Hospital, St. Louis, Missouri2
1 shared publicationChristopher Colocillo
Nalge Nunc International, Rochester, NY, USA
1 shared publicationDavid Cutter
Wyeth Vaccines Research, Pearl River, New York 10965,1 Edward Mallinckrodt Department of Pediatrics and Department of Molecular Microbiology, Washington University School of Medicine, and Division of Infectious Diseases, St. Louis Children's Hospital, St. Louis, Missouri2
1 shared publicationDeborah A. Dilts
Vaccines Research, Wyeth, Pearl River, NY, USA
1 shared publication
Latest Publications
- 1 June 2007
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 75 (6) , 2818-2825
Moraxella catarrhalis Outer Membrane Protein CD Elicits Antibodies That Inhibit CD Binding to Human Mucin and Enhance Pulmonary Clearance of M. catarrhalis in a Mouse Model
The outer membrane protein CD of Moraxella catarrhalis is considered to be a potential vaccine antigen against Moraxella infection. We purified the native CD from isolate O35E, administered it to mice, and detected considerable titers of anti-CD antibodies. Anti-CD sera were cross-reactive towards six different M. catarrhalis isolates and promoted bacterial clearance of O35E in a pulmonary challenge model. To circumvent the difficulty of generating large quantities of CD from M. catarrhalis for vaccine use, the CD gene from O35E was cloned into Escherichia coli , and the recombinant CD, expressed without a signal sequence or fusion tags, represented ∼70% of the total E. coli proteins. The recombinant CD formed inclusion bodies that were solubilized with 6 M urea and then purified by ion-exchange chromatography, a procedure that produced soluble CD of high purity and yield. Mice immunized with the purified recombinant CD had significant titers of anti-CD antibodies that were cross-reactive towards 24 different M. catarrhalis isolates. Upon challenge, these mice showed enhanced bacterial clearance of both O35E and a heterologous M. catarrhalis isolate, TTA24. In an in vitro assay, antisera to either the native or the recombinant CD inhibited the binding activity of CD to human tracheobronchial mucin in a serum concentration-dependent manner, and the extent of inhibition appeared to correlate with the corresponding anti-CD antibody titer and whole-cell enzyme-linked immunosorbent assay titer. Our results demonstrate that the recombinant CD is a promising vaccine candidate for preventing Moraxella infection.
- 1 June 2007
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 75 (6) , 2818-2825
Moraxella catarrhalis Outer Membrane Protein CD Elicits Antibodies That Inhibit CD Binding to Human Mucin and Enhance Pulmonary Clearance of M. catarrhalis in a Mouse Model
The outer membrane protein CD of Moraxella catarrhalis is considered to be a potential vaccine antigen against Moraxella infection. We purified the native CD from isolate O35E, administered it to mice, and detected considerable titers of anti-CD antibodies. Anti-CD sera were cross-reactive towards six different M. catarrhalis isolates and promoted bacterial clearance of O35E in a pulmonary challenge model. To circumvent the difficulty of generating large quantities of CD from M. catarrhalis for vaccine use, the CD gene from O35E was cloned into Escherichia coli , and the recombinant CD, expressed without a signal sequence or fusion tags, represented ∼70% of the total E. coli proteins. The recombinant CD formed inclusion bodies that were solubilized with 6 M urea and then purified by ion-exchange chromatography, a procedure that produced soluble CD of high purity and yield. Mice immunized with the purified recombinant CD had significant titers of anti-CD antibodies that were cross-reactive towards 24 different M. catarrhalis isolates. Upon challenge, these mice showed enhanced bacterial clearance of both O35E and a heterologous M. catarrhalis isolate, TTA24. In an in vitro assay, antisera to either the native or the recombinant CD inhibited the binding activity of CD to human tracheobronchial mucin in a serum concentration-dependent manner, and the extent of inhibition appeared to correlate with the corresponding anti-CD antibody titer and whole-cell enzyme-linked immunosorbent assay titer. Our results demonstrate that the recombinant CD is a promising vaccine candidate for preventing Moraxella infection.
- Open Access
- 1 August 2006
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 47 (3) , 343-350
Polymorphism of the major surface epitope of the CopB outer membrane protein ofMoraxella catarrhalis
The CopB outer membrane protein has been considered a vaccine candidate for the prevention of infections due to Moraxella catarrhalis. Monoclonal ant
- 1 August 2006
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 47 (3) , 343-350
Open AccessPolymorphism of the major surface epitope of the CopB outer membrane protein ofMoraxella catarrhalis
The CopB outer membrane protein has been considered a vaccine candidate for the prevention of infections due to Moraxella catarrhalis. Monoclonal ant
- Open Access
- 1 December 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (12) , 6961-6968
The C-Terminal Fragment of the Internal 110-Kilodalton Passenger Domain of the Hap Protein of NontypeableHaemophilus influenzaeIs a Potential Vaccine Candidate
NontypeableHaemophilus influenzaeis a major causative agent of bacterial otitis media in children.H. influenzaeHap autotransporter protein is an adhesin composed of an outer membrane Hapβ region and a moiety of an extracellular internal 110-kDa passenger domain called HapS. The HapSmoiety promotes adherence to human epithelial cells and extracellular matrix proteins, and it also mediates bacterial aggregation and microcolony formation. A recent work (D. L. Fink, A. Z. Buscher, B. A. Green, P. Fernsten, and J. W. St. Geme, Cell. Microbiol.5:175-186, 2003) demonstrated that HapSadhesive activity resides within the C-terminal 311 amino acids (the cell binding domain) of the protein. In this study, we immunized mice subcutaneously with recombinant proteins corresponding to the C-terminal region of HapSfromH. influenzaestrains N187, P860295, and TN106 and examined the resulting immune response. Antisera against the recombinant proteins from all three strains not only recognized native HapSpurified from strain P860295 but also inhibitedH. influenzaeHap-mediated adherence to Chang epithelial cells. Furthermore, when mice immunized intranasally with recombinant protein plus mutant cholera toxin CT-E29H were challenged with strain TN106, they were protected against nasopharyngeal colonization. These observations demonstrate that the C-terminal region of HapSis capable of eliciting cross-reacting antibodies that reduce nasopharyngeal colonization, suggesting utility as a vaccine antigen for the prevention of nontypeableH. influenzaediseases.
- 1 December 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (12) , 6961-6968
Open AccessThe C-Terminal Fragment of the Internal 110-Kilodalton Passenger Domain of the Hap Protein of NontypeableHaemophilus influenzaeIs a Potential Vaccine Candidate
NontypeableHaemophilus influenzaeis a major causative agent of bacterial otitis media in children.H. influenzaeHap autotransporter protein is an adhesin composed of an outer membrane Hapβ region and a moiety of an extracellular internal 110-kDa passenger domain called HapS. The HapSmoiety promotes adherence to human epithelial cells and extracellular matrix proteins, and it also mediates bacterial aggregation and microcolony formation. A recent work (D. L. Fink, A. Z. Buscher, B. A. Green, P. Fernsten, and J. W. St. Geme, Cell. Microbiol.5:175-186, 2003) demonstrated that HapSadhesive activity resides within the C-terminal 311 amino acids (the cell binding domain) of the protein. In this study, we immunized mice subcutaneously with recombinant proteins corresponding to the C-terminal region of HapSfromH. influenzaestrains N187, P860295, and TN106 and examined the resulting immune response. Antisera against the recombinant proteins from all three strains not only recognized native HapSpurified from strain P860295 but also inhibitedH. influenzaeHap-mediated adherence to Chang epithelial cells. Furthermore, when mice immunized intranasally with recombinant protein plus mutant cholera toxin CT-E29H were challenged with strain TN106, they were protected against nasopharyngeal colonization. These observations demonstrate that the C-terminal region of HapSis capable of eliciting cross-reacting antibodies that reduce nasopharyngeal colonization, suggesting utility as a vaccine antigen for the prevention of nontypeableH. influenzaediseases.